key: cord-0941053-m8xxr6xq
authors: Sun, Weina; Leist, Sarah R.; McCroskery, Stephen; Liu, Yonghong; Slamanig, Stefan; Oliva, Justine; Amanat, Fatima; Schäfer, Alexandra; Dinnon, Kenneth H.; García-Sastre, Adolfo; Krammer, Florian; Baric, Ralph S.; Palese, Peter
title: Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate
date: 2020-07-28
journal: bioRxiv
DOI: 10.1101/2020.07.26.221861
sha: 38211994d9c7756bbc693388a4af047baf137270
doc_id: 941053
cord_uid: m8xxr6xq

Due to the lack of protective immunity of humans towards the newly emerged SARS-CoV-2, this virus has caused a massive pandemic across the world resulting in hundreds of thousands of deaths. Thus, a vaccine is urgently needed to contain the spread of the virus. Here, we describe Newcastle disease virus (NDV) vector vaccines expressing the spike protein of SARS-CoV-2 in its wild type or a pre-fusion membrane anchored format. All described NDV vector vaccines grow to high titers in embryonated chicken eggs. In a proof of principle mouse study, we report that the NDV vector vaccines elicit high levels of antibodies that are neutralizing when the vaccine is given intramuscularly. Importantly, these COVID-19 vaccine candidates protect mice from a mouse-adapted SARS-CoV-2 challenge with no detectable viral titer and viral antigen in the lungs. Research in context Evidence before this study The spike (S) protein of the SARS-CoV-2 is the major antigen that notably induces neutralizing antibodies to block viral entry. Many COVID-19 vaccines are under development, among them viral vectors expressing the S protein of SARS-CoV-2 exhibit many benefits. Viral vector vaccines have the potential of being used as both live or inactivated vaccines and they can induce Th1 and Th2-based immune responses following different immunization regimens. Additionally, viral vector vaccines can be handled under BSL-2 conditions and they grow to high titers in cell cultures or other species restricted-hosts. For a SARS-CoV-2 vaccine, several viral vectors are being tested, such as adenovirus, measles virus and Modified vaccinia Ankara. Added value of this study The NDV vector vaccine against SARS-CoV-2 described in this study has advantages similar to those of other viral vector vaccines. But the NDV vector can be amplified in embryonated chicken eggs, which allows for high yields and low costs per dose. Also, the NDV vector is not a human pathogen, therefore the delivery of the foreign antigen would not be compromised by any pre-existing immunity in humans. Finally, NDV has a very good safety record in humans, as it has been used in many oncolytic virus trials. This study provides an important option for a cost-effective SARS-CoV-2 vaccine. Implications of all the available evidence This study informs of the value of a viral vector vaccine against SARS-CoV-2. Specifically, for this NDV based SARS-CoV-2 vaccine, the existing egg-based influenza virus vaccine manufactures in the U.S. and worldwide would have the capacity to rapidly produce hundreds of millions of doses to mitigate the consequences of the ongoing COVID-19 pandemic.

The unprecedented coronavirus disease 2019 pandemic caused by severe acute respiratory 61 syndrome coronavirus 2 (SARS-CoV-2) has resulted in ~16.3 million infections with more than half a 62 million deaths since the end of 2019 as of July 26 th 2020, and continues to pose a threat to public health.

To mitigate the spread of the virus, social distancing, mask-wearing, and the lockdown of cities, states or 64 even countries were practiced, with a heavy price paid both medically and economically. Unfortunately, 65 due to the relative lack of pre-existing immunity of humans to this virus, no countermeasures will be 66 completely effective without a vaccine. Because of the urgent need for an effective SARS-CoV-2 vaccine, 67 many candidates are being developed using various vaccine platforms, including mRNA vaccines (1, 2), 68 inactivated whole virus vaccines (3), subunit vaccines, DNA vaccines and viral vector vaccines (4). These 69 vaccine candidates are designed to essentially target the spike (S) protein of the SARS-CoV-2 (5), which 70 is the major structural protein displayed on the surface of the SARS-CoV-2. The S protein mediates the 71 entry of the virus via binding to the angiotensin converting enzyme 2 (ACE2) receptor in humans. The S 72 protein is also the most important antigen of the virus that harbors many B cell and T cell epitopes (6-9).

Neutralizing antibodies, most of which target the receptor-binding domain (RBD), can be induced by the 74 S protein (9, 10). However, to eventually contain the virus spread worldwide, not only the efficacy, but 75 also the cost and scalability of the vaccine are crucial, especially in low and middle income countries with 76 limited resources. Paramyxoviridae, it is an avian pathogen, typically causing no symptoms in humans although mild 81 influenza-like symptoms or conjunctivitis have been described in rare cases. The lentogenic NDV vaccine 82 strain such as the LaSota strain, in addition to be avirulent in birds, has been used as an oncolytic agent 83 and a vaccine vector (11-15). As a large negative strand RNA virus, NDV is stable and well tolerates 84 transgenes into its genome. NDV vectors have been successfully used to express the spike protein of other 85 coronaviruses (16, 17) . The NDV platform is also appealing, because the virus grows to high titers in 86 embryonated chicken eggs, which are also used to produce influenza virus vaccines. Humans typically 87 lack pre-existing immunity toward the NDV, which makes the virus preferable over other viral vectors 88 that are human pathogens, such as human adenovirus, measles virus or Modified Vaccinia Ankara (MVA).

The lentogenic NDV vector has proven to be safe in humans as it has been tested extensively in human 90 trials (18-20) . Most importantly, at low cost, NDV vector vaccines could be generated in embryonated 91 chicken eggs quickly under biosafety level 2 (BSL-2) conditions to meet the vast demand on a global 92 scale. In this study, we have successfully rescued NDV vectors expressing two forms of the spike protein 93 of SARS-CoV-2, the wild type (WT) S and a chimeric version containing the ectodomain (with the 94 polybasic cleavage site deleted) of the spike and the transmembrane domain and cytoplasmic domain of 95 the NDV F (pre-fusion S-F chimera). We have shown that WT S and S-F were well expressed from the 96 NDV as transgenes in infected cells. While both WT S and S-F were displayed on the surface of the NDV 97 particles, the incorporation of the S-F into NDV particles was substantially improved compared to that of 98 the WT S, as expected. A proof of concept study in mice using three live NDV vectors expressing the 99 spike protein (NDV_LS_S, NDV_LS_S-F and NDV_LS/L289A_S-F) showed that high titers of binding 100 and neutralizing antibodies were induced. All three NDV vector vaccines fully protected mice from 101 challenge with a SARS-CoV-2 mouse-adapted strain, showing no detectable viral titers and viral antigens 102 in the lungs at day four post-challenge. To conclude, we have developed promising cost-effective SARS-CoV-2 vaccine candidates using the NDV LaSota strain as the viral vector, which could be generated to 104 high yield under BSL-2 conditions. 105 106

The sequence of the wild type S was amplified from pCAGGS plasmid (21) fusion (23). The latter NDV mutant has been safely used in humans (15) (Fig. 1B) . NDV expressing the 294 spike proteins were rescued by transient transfection of BSRT7 cells followed by amplification in 295 embryonated chicken eggs. All the viruses expressing the S or S-F grew to high titers (~10 8 FFU/ml) in 296 embryonated chicken eggs (Fig. 1C) , which is advantageous for the development of a low-cost vaccine.

To validate the expression of S and S-F as transgenes, Vero E6 cells were infected with WT NDV or 300 NDV expressing the S or S-F. The surface of the cells was stained with anti-NDV rabbit serum or spike-301 specific monoclonal antibody CR3022 that recognizes the RBD. We confirmed that only NDV expressing 302 the S or S-F showed robust expression of the spike on the cell surface, while NDV proteins were detected 303 in all virus-infected cells ( Fig. 2A) . This demonstrates that S and S-F are successfully expressed by the 304 NDV. To examine the incorporation of the S and S-F into the NDV virions, we concentrated the 305 NDV_LS_S, NDV_LS_S-F and NDV_LS/L289A_S-F through a 20% sucrose cushion. The pellets were re-suspended in PBS. The WT NDV_LS was prepared the same way and was used as the negative control.

The protein content of each concentrated virus was determined by BCA assay. Two micrograms of each 308 virus was resolved on an SDS-PAGE. A Western blot was performed to examine the abundance of the 309 spike using mouse monoclonal antibody 2B3E5 that binds to a linear epitope of the S1 protein. The 310 expression of the NDV viral hemagglutinin-neuraminidase (HN) protein was also shown as an internal 311 control of the concentrated viruses (Fig. 2B) . As expected, both S and S-F incorporated into the NDV 312 particles. Of note, the WT S harboring the polybasic cleavage site (CS) was completely cleaved showing 313 only the S1, while the S-F was maintained at its pre-fusion S0 stage. Importantly, the S-F expressed either 314 by the WT or L289A NDV_LS backbone exhibited superior incorporation into the virions over the WT S 315 shown by much higher abundance of S-F than S1 cleaved from the WT S (Fig. 2B ). This confirms that the 316 TM/CT of F in the S-F chimera indeed facilitates the membrane-anchoring of the spike as expected. Since and 2) were used as vector-only controls. Mice receiving only the PBS (group 9) were used as negative 332 controls. Mouse sera from the two bleedings were harvested. Serum IgG titers and neutralizing antibody 333 titers were measured by ELISAs and microneutralization assays, respectively. To perform ELISA, full-334 length trimeric spike protein was coated onto ELISA plates. The endpoint titers of serum IgG were used 335 as the readout (Fig. 3B) . After one immunization, all the NDV constructs expressing the spike protein 336 elicited S-binding antibodies, whereas WT NDV constructs and PBS controls show negligible antibody 337 binding signals. The second immunization significantly increased the antibody titers around 1 week after 338 the boost without showing significant difference among the three NDV constructs (Fig. 3B) . The 339 neutralizing activity of the antibodies was measured in a microneutralization assay using the USA-340 WA1/2020 SARS-CoV-2 strain. Pooled sera from each group were tested in a technical duplicate. The 341 ID 50 value was calculated as the readout of neutralizing activity of post-boost sera (Day 29). Sera from all 342 vaccinated groups showed neutralizing activity. The neutralization titer of sera from the NDV_LS_S 343 high-dose (50 µg) vaccination group (ID 50 ≈ 444) appeared to be slightly higher than that from the low-344 dose (10 µg) vaccination group (ID 50 ≈178). No substantial difference was observed between the low-345 dose and high-dose groups using the NDV_LS_S-F and NDV_LS/L289A_S-F constructs (Fig. 3C) , the 346 neutralization titers of which are comparable to that of the NDV_LS_S high-dose (50 µg) group. To 347 summarize, all the NDV vectors that were engineered to express the S or S-F elicited high titers of 348 binding and neutralizing antibodies in mice. The WT S and S-F constructs appeared to exhibit similar 349 immunogenicity when expressed by live NDV vectors that were given intramuscularly to mice. interval. Mice were bled pre-boost and 8 days after the boost. Mice were challenged with a mouse-568 adapted SARS-CoV-2 MA strain 11 days after the boost. A total of ten groups of mice were used in a 569 vaccination and challenge study. Group 1 (10 µg) and 2 (50 µg) received the WT NDV; Group 3 (10 µg) 570 and 4 (50 µg) received the NDV_LS_S; Group 5 (10 µg) and 6 (50 µg) received NDV_LS_S-F; Group 7 571 (10 µg) and 8 (50 µg) received NDV_LS/L289A_S-F; Group 9 received PBS as negative controls. An 572 age-matched healthy control group 10 was provided upon challenge. (B) Spike-specific serum IgG titers 573 measured by ELISAs. Sera from animals at 3 weeks after-prime (patterned bars) and 8 days after-boost 574 (solid bars) were isolated. Serum IgG was measured against a recombinant trimeric spike protein by 575 ELISAs. The endpoint titers were calculated as the readout for ELISAs. (C) Neutralization titers of serum 576 antibodies. Sera from 3 weeks after-prime and 8 days after-boost were pooled within each group.

Technical duplicates were performed to measure neutralization activities of serum antibodies using a 578 USA-WA1/2020 SARS-CoV-2 strain. The ID50 value was calculated as the readout of the neutralization 579 assay. For the samples (WT NDV and PBS groups) showing no neutralizing activity in the assay, an ID50 580 of 10 was given as the starting dilution of the sera is 1:20 (LoD: limit of detection). 

SARS-CoV-2 mRNA Vaccine Development Enabled by 436

Prototype Pathogen Preparedness

An mRNA Vaccine 442 against SARS-CoV-2 -Preliminary Report

Rapid development of an 446 inactivated vaccine candidate for SARS-CoV-2

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored 450

COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

SARS-CoV-2 Vaccines: Status Report

SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

A Sequence Homology 459 and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses

Preliminary Identification of Potential Vaccine 462 Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological 463 Studies

Potential SARS-CoV-2 Preimmune IgM Epitopes

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV 470 antibody

Rescue of Newcastle disease virus from 472 cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence

Generation of 475 recombinant lentogenic Newcastle disease virus from cDNA

Oncolytic Newcastle disease virus for cancer therapy: old challenges 477 and new directions

Recombinant Newcastle disease virus as 479 a vaccine vector for cancer therapy

Oncolytic Newcastle disease virus expressing a 481 checkpoint inhibitor as a radioenhancing agent for murine melanoma

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for 484 intranasal immunization against emerging pathogens

Newcastle 486 disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing 487 antibodies in Bactrian camels

Phase I/II trial of intravenous NDV-490 HUJ oncolytic virus in recurrent glioblastoma multiforme

Phase I trial of 493 intravenous administration of PV701, an oncolytic virus

Fifty Years of Clinical Application of Newcastle Disease Virus: Time to 496

A serological assay to detect SARS-CoV-2 seroconversion in 502 humans

Design and Production of Newcastle Disease Virus for 504

Decreased dependence on receptor recognition 506 for the fusion promotion activity of L289A-mutated newcastle disease virus fusion protein 507 correlates with a monoclonal antibody-detected conformational change

Human monoclonal antibody combination against SARS coronavirus: synergy 511 and coverage of escape mutants

A highly 513 conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

A mouse-adapted SARS-CoV-2 model for the 518 evaluation of COVID-19 medical countermeasures

Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Engineered viral vaccine 524 constructs with dual specificity: avian influenza and Newcastle disease

The convalescent sera option for containing COVID-19

Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and

Life-threatening COVID-19: A Randomized Clinical Trial

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, 538 multicentre trial